Agios axes 100-plus R&D roles while awaiting FDA decision
Agios Pharmaceuticals is axing over 35% of its R&D team in a commercial-focused restructuring that analysts view favorably. The Massachusetts…
Agios Pharmaceuticals is axing over 35% of its R&D team in a commercial-focused restructuring that analysts view favorably. The Massachusetts…